| Year |
Citation |
Score |
| 2024 |
Jess J, Sorensen KM, Boguslawski EA, Stout MC, Madaj ZB, Caiello BP, Pomaville M, Wilson ER, Kinn-Gurzo SS, Parker CC, Veluvolu SM, Brysgel TV, Kaufman R, Kitchen-Goosen SM, Gedminas JM, ... Grohar PJ, et al. Cell Context is the third axis of synergy for the combination of ATR inhibition and cisplatin in Ewing sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38506712 DOI: 10.1158/1078-0432.CCR-23-3063 |
0.355 |
|
| 2022 |
Deng Q, Natesan R, Cidre-Aranaz F, Arif S, Liu Y, Rasool RU, Wang P, Mitchell-Velasquez E, Das CK, Vinca E, Cramer Z, Grohar PJ, Chou M, Kumar-Sinha C, Weber K, et al. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1. Cell Reports. 39: 110971. PMID 35705030 DOI: 10.1016/j.celrep.2022.110971 |
0.339 |
|
| 2022 |
Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Molecular Cancer Therapeutics. PMID 35657345 DOI: 10.1158/1535-7163.MCT-21-1003 |
0.367 |
|
| 2020 |
Chasse MH, Johnson BK, Boguslawski EA, Sorensen KM, Rosien JE, Kang MH, Reynolds CP, Heo L, Madaj ZB, Beddows I, Foxa GE, Kitchen-Goosen SM, Williams BO, Triche TJ, Grohar PJ. Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. Embo Molecular Medicine. e12640. PMID 33332735 DOI: 10.15252/emmm.202012640 |
0.3 |
|
| 2020 |
Gedminas JM, Chasse MH, McBrairty M, Beddows I, Kitchen-Goosen SM, Grohar PJ. Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor. Oncogenesis. 9: 41. PMID 32345977 DOI: 10.1038/s41389-020-0224-1 |
0.37 |
|
| 2020 |
Flores G, Everett JH, Boguslawski EA, Oswald BM, Madaj ZB, Beddows I, Dikalov S, Adams M, Klumpp-Thomas CA, Kitchen-Goosen SM, Martin SE, Caplen NJ, Helman LJ, Grohar PJ. CDK9 Blockade Exploits Context-Dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma. Molecular Cancer Therapeutics. PMID 32127464 DOI: 10.1158/1535-7163.Mct-19-0775 |
0.444 |
|
| 2019 |
Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, Ley AM, Zhang M, Hong JA, Venzon D, Jackson JP, Brouwer KR, Grohar P, Glod J, et al. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altering Expression of Hepatocellular Bile Transporters. Molecular Pharmacology. PMID 31175181 DOI: 10.1124/Mol.118.114827 |
0.346 |
|
| 2019 |
Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, et al. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000research. 8. PMID 31031965 DOI: 10.12688/F1000Research.18139.1 |
0.322 |
|
| 2019 |
Harlow ML, Chasse MH, Boguslawski EA, Sorensen KM, Gedminas JM, Kitchen-Goosen SM, Rothbart SB, Taslim C, Lessnick SL, Peck AS, Madaj ZB, Bowman MJ, Grohar PJ. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule Dependent Manner. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30723142 DOI: 10.1158/1078-0432.Ccr-18-3511 |
0.421 |
|
| 2019 |
Flores G, Kitchen-Goosen S, Oswald B, Boguslawski E, Adams M, Beddows I, Madaj Z, Grohar P. Abstract 2882: Mithramycin impedes EWS-FLI1 driven transcription by preventing target promoter clearance Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2882 |
0.374 |
|
| 2019 |
Chasse MH, Boguslawski E, Sorensen K, Beddows I, Rybski K, Madaj Z, Kitchen-Goosen SM, Grohar PJ. Abstract 2883: Mithramycin inhibits KDM6A (UTX) and SWI/SNF to induce apoptosis in malignant rhabdoid tumor Cancer Research. 79: 2883-2883. DOI: 10.1158/1538-7445.Am2019-2883 |
0.427 |
|
| 2018 |
Chasse MH, Boguslawski EA, Sorensen KM, Wernette CE, Goosen SM, Grohar PJ. Abstract A32: Therapeutically targeting PRC2 expression and dynamics in rhabdoid tumor Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-A32 |
0.459 |
|
| 2018 |
Chasse MH, Boguslawski E, Wernette CE, Kitchen-Goosen S, Grohar PJ. Abstract 4634: Mithramycin amplifies the imbalance between the BAF and PRC2 complexes to drive apoptosis in rhabdoid tumor Cancer Research. 78: 4634-4634. DOI: 10.1158/1538-7445.Am2018-4634 |
0.44 |
|
| 2018 |
Flores G, Everett J, Oswald B, Caplen N, Helman L, Madaj Z, Grohar P. Abstract 1632: Suppression of EWS-FLI1 transcription using a combination therapy of mithramycin and cyclin-dependent kinase 9 inhibition Cancer Research. 78: 1632-1632. DOI: 10.1158/1538-7445.Am2018-1632 |
0.497 |
|
| 2017 |
Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemotherapy and Pharmacology. PMID 28735378 DOI: 10.1007/S00280-017-3382-X |
0.324 |
|
| 2017 |
Harlow M, Boguslawski E, Peck A, Madaj Z, Navarro MJ, Aviles P, Galmarini C, Grohar P. Abstract LB-047: Optimizing the trabectedin-mediated inhibition of EWS-FLI1 activity by schedule and fusion type Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-047 |
0.419 |
|
| 2016 |
Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D'Incalci M, von Luettichau I, Grohar PJ, Berdel WE, Burdach S. Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. Sarcoma. 2016: 7461783. PMID 27843394 DOI: 10.1155/2016/7461783 |
0.355 |
|
| 2016 |
Harlow ML, Maloney N, Roland J, Guillén-Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, ... ... Grohar PJ, et al. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Research. PMID 27697767 DOI: 10.1158/0008-5472.Can-16-0568 |
0.467 |
|
| 2016 |
Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ. (18)F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Scientific Reports. 6: 33926. PMID 27671553 DOI: 10.1038/Srep33926 |
0.312 |
|
| 2016 |
Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen SM, Segars LE, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang MH, Smith MA, Turner L, Madaj ZB, Winn ME, ... ... Grohar PJ, et al. Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26979396 DOI: 10.1158/1078-0432.Ccr-15-2624 |
0.42 |
|
| 2016 |
Caropreso V, Darvishi E, Turbyville TJ, Ratnayake R, Grohar PJ, McMahon JB, Woldemichael G. Englerin A inhibits EWS-FLI1 DNA Binding in Ewings Sarcoma Cells. The Journal of Biological Chemistry. PMID 26961871 DOI: 10.1074/Jbc.M115.701375 |
0.335 |
|
| 2016 |
Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, et al. The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. PMID 26802024 DOI: 10.18632/Oncotarget.6937 |
0.384 |
|
| 2016 |
Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, et al. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma. Cell Reports. PMID 26776507 DOI: 10.1016/J.Celrep.2015.12.063 |
0.433 |
|
| 2016 |
Harlow M, Easton M, Navarro MJG, Turner L, Hostetter G, Galmarini C, Aviles P, Grohar P. Abstract LB-177: PM01183 inactivates the EWS/FLI1 transcription factor by redistributing the protein within the nucleus Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-177 |
0.459 |
|
| 2016 |
Kim S, Olivero C, Rivera GOR, Sen N, Haddock S, Huppi K, Helman LJ, Grohar PJ, Caplen NJ. Abstract 2008: Ewing sarcoma cells harboring a translocation that retains EWSR1 exon 8 require HNRNPH1 to express the in-frame oncogenic fusion transcript EWS-FLI1 Cancer Research. 76: 2008-2008. DOI: 10.1158/1538-7445.Am2016-2008 |
0.394 |
|
| 2015 |
Tancredi R, Zambelli A, DaPrada GA, Fregoni V, Pavesi L, Riccardi A, Burdach S, Grohar PJ, D'Incalci M. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer Chemotherapy and Pharmacology. 75: 1317-20. PMID 25809543 DOI: 10.1007/S00280-015-2726-7 |
0.398 |
|
| 2015 |
Grohar PJ, Kim S, Haddock S, Rivera GR, Harlow M, Maloney NK, Huppi K, Gehlhaus K, Grandin M, Klumpp-Thomas C, Buehler E, Helman LJ, Martin SE, Caplen NJ. Abstract 479: Inhibition of the splicing of the EWS-FLI1 fusion transcript reverses EWS-FLI1 driven oncogenic expression in Ewing sarcoma Cancer Research. 75: 479-479. DOI: 10.1158/1538-7445.Am2015-479 |
0.484 |
|
| 2015 |
Osgood C, Maloney N, Kidd CG, Gebregiorgis M, Nunez LE, Gonzalez-Sabin J, Helman LJ, Moris F, Grohar PJ. Abstract 1612: Identification of mithramycin analogs with improved targeting of the EWS/FLI1 transcription factor Cancer Research. 75: 1612-1612. DOI: 10.1158/1538-7445.Am2015-1612 |
0.444 |
|
| 2014 |
Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1190-203. PMID 24277455 DOI: 10.1158/1078-0432.Ccr-13-0901 |
0.443 |
|
| 2014 |
Kim S, Grohar PJ, Klumpp C, Lal A, Martin SE, Helman LJ, Caplen NJ. Abstract 520: Functional genomic screens identify microRNA regulators of the oncogenic fusion transcription factor EWS-FLI1 Cancer Research. 74: 520-520. DOI: 10.1158/1538-7445.Am2014-520 |
0.353 |
|
| 2014 |
Harlow M, Maloney N, Navarro MJG, D'Incalci M, Galmarini C, Marin PMA, Grohar P. Abstract 3962: PM01183 shows an improved therapeutic index relative to trabectedin and suppresses EWS/FLI1 activity at clinically achievable concentrations Cancer Research. 74: 3962-3962. DOI: 10.1158/1538-7445.Am2014-3962 |
0.442 |
|
| 2013 |
Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL. A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group. Frontiers in Oncology. 3: 57. PMID 23519678 DOI: 10.3389/Fonc.2013.00057 |
0.312 |
|
| 2013 |
Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 32: 5429-38. PMID 23318429 DOI: 10.1038/Onc.2012.590 |
0.373 |
|
| 2013 |
Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacology & Therapeutics. 137: 216-24. PMID 23085431 DOI: 10.1016/J.Pharmthera.2012.10.004 |
0.396 |
|
| 2013 |
Harlow M, Maloney N, Segars L, Woldemichael G, Helman LJ, Grohar PJ. Abstract 2760: Identification of ET-743 analogs with improved selectivity and potency for EWS-FLI1 and Ewing sarcoma cells. Cancer Research. 73: 2760-2760. DOI: 10.1158/1538-7445.Am2013-2760 |
0.438 |
|
| 2013 |
McCalla A, Grohar P, Martin S, Buehler E, Kim S, Caplen N, Morris J, Kunkel M, Evans D, Monks A, Teicher B, Helman L. Abstract C222: The identification of kinase targets in Ewing sarcoma cell lines using RNAi and high-throughput investigational agents screens. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C222 |
0.415 |
|
| 2012 |
Segars LE, Mendoza A, Helman LJ, Grohar PJ. Abstract 2497: ET-743 interferes with EWS-FLI1 driven WRN expression in Ewing sarcoma cells and sensitizes to topoisomerase I inhibitors Cancer Research. 72: 2497-2497. DOI: 10.1158/1538-7445.Am2012-2497 |
0.456 |
|
| 2012 |
Gebregiorgis M, Woldemichael G, He M, Kang MH, Núñez LE, Morís F, Smith MA, Helman LJ, Grohar PJ. Abstract 2494: Identification of mithramycin analogues with increased potency and more selective inhibition of EWS-FLI1 for the treatment of Ewing sarcoma Cancer Research. 72: 2494-2494. DOI: 10.1158/1538-7445.Am2012-2494 |
0.458 |
|
| 2011 |
Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. Journal of the National Cancer Institute. 103: 962-78. PMID 21653923 DOI: 10.1093/Jnci/Djr156 |
0.455 |
|
| 2011 |
Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia (New York, N.Y.). 13: 145-53. PMID 21403840 DOI: 10.1593/Neo.101202 |
0.442 |
|
| 2011 |
Segars LE, Mendoza A, Helman LJ, Grohar PJ. Abstract A103: ET-743 and irinotecan cooperate to inhibit the EWS/FLI1 transcription factor and the associated DNA damage response. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A103 |
0.426 |
|
| 2010 |
Arnaldez FI, Yeung CL, Grohar PJ, Helman LJ. Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth. Journal of Clinical Oncology. 28: 9525-9525. DOI: 10.1200/Jco.2010.28.15_Suppl.9525 |
0.407 |
|
| 2010 |
Grohar PJ, Woldemichael GM, Griffin LB, Yeung C, Chen Q, Khanna C, Khan J, McMahon JB, Helman LJ. Abstract 3414: High-throughput screening identifies mithramycin as a potent inhibitor of the EWS-FLI1 transcription factor and a strong cytotoxic agent in Ewing's sarcoma cells Cancer Research. 70: 3414-3414. DOI: 10.1158/1538-7445.Am10-3414 |
0.477 |
|
| 2006 |
Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 26: 1932-40. PMID 17001314 DOI: 10.1038/Sj.Onc.1209990 |
0.347 |
|
| 2004 |
Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Research. 64: 728-35. PMID 14744791 DOI: 10.1158/0008-5472.Can-03-2456 |
0.381 |
|
| 2001 |
Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, et al. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. Journal of Medicinal Chemistry. 44: 1915-26. PMID 11384237 DOI: 10.1021/Jm0004291 |
0.316 |
|
| 2000 |
Meroueh M, Grohar PJ, Qiu J, SantaLucia J, Scaringe SA, Chow CS. Unique structural and stabilizing roles for the individual pseudouridine residues in the 1920 region of Escherichia coli 23S rRNA. Nucleic Acids Research. 28: 2075-83. PMID 10773075 DOI: 10.1093/Nar/28.10.2075 |
0.515 |
|
| 1999 |
Grohar PJ, Chow CS. A practical synthesis of the modified RNA nucleoside pseudouridine Tetrahedron Letters. 40: 2049-2052. DOI: 10.1016/S0040-4039(99)00162-8 |
0.509 |
|
| Show low-probability matches. |